# Arcturus Therapeutics Holdings Inc.: Form 10-Q for the period ended Mar 31, 2022

- Company: [Arcturus Therapeutics Holdings Inc.](/companies/arct.md) (CIK 1768224)
- Form: 10-Q
- Filed: 2022-05-09
- Accepted by EDGAR: May 9, 2022, 16:31 ET
- Period: 2022-03-31
- Accession: 0000950170-22-008524
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1768224/000095017022008524/arct-20220331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1768224/000095017022008524/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-01-01 to 2022-03-31 | $5.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2022-01-01 to 2022-03-31 | $44.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-01-01 to 2022-03-31 | −$50.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-01-01 to 2022-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-01-01 to 2022-03-31 | −$51.2m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months, 2022-01-01 to 2022-03-31 | −$49.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2022-01-01 to 2022-03-31 | $2.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-03-31 | $319.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-03-31 | $327.0m | us-gaap:AssetsCurrent |
| Total assets | at 2022-03-31 | $342.0m | us-gaap:Assets |
| Current liabilities | at 2022-03-31 | $107.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-03-31 | $157.2m | us-gaap:Liabilities |
| Long-term debt | at 2022-03-31 | $39.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2022-03-31 | $24.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2022-03-31 | $184.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 37,286 characters.

*The following is a discussion of the financial condition and results of operations of Arcturus Therapeutics Holdings Inc. for the three month period ended March 31, 2022. Unless otherwise specified herein, references to the “Company,” “Arcturus,” “we,” “our” and “us” mean Arcturus Therapeutics Holdings Inc. and its consolidated subsidiaries. You should read the following discussion and analysis together with the interim condensed consolidated financial statements and related notes included elsewhere herein. For additional information relating to our management’s discussion and analysis of financial conditions and results of operations, please see our Annual Report on Form 10‑K for the year ended December 31, 2021 (the “2021 Annual Report”), which was filed with the U.S. Securities and Exchange Commission (the “Commission”) on March 1, 2022. Unless otherwise defined herein, capitalized words and expressions used herein shall have the same meanings ascribed to them in the 2021 Annual Report.*

*This report includes forward-looking statements which, although based on assumptions that we consider reasonable, are subject to risks and uncertainties which could cause actual events or conditions to differ materially from those currently anticipated and expressed or implied by such forward-looking statements.*

*You should read this report and the documents that we reference in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. You should also review the factors and risks we describe in the reports we will file or submit from time to time with the Commission after the date of this report.*

### Overview

Arcturus is a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to our messenger RNA (“mRNA”) platform, our proprietary lipid nanoparticle delivery system, LUNAR®, has the potential to enable multiple nucleic acid medicines, and our proprietary self-amplifying mRNA technology (Self-Transcribing and Replicating RNA or STARR™) technology has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels.

We are leveraging our proprietary platform relating to LUNAR and our nucleic acid technologies to develop and advance a pipeline of mRNA based vaccines and therapeutics for the prevention of infectious diseases and treatment of rare genetic disorders with significant unmet medical needs. We continue to expand this platform with innovative delivery solutions that allow us to expand our discovery efforts. Our proprietary LUNAR technology is intended to address the major hurdles in RNA drug development, namely the effective and safe delivery of RNA therapeutics to disease-relevant target tissues. We believe the versatility of our platform to target multiple tissues, its compatibility with various nucleic acid therapeutics, and our expertise in developing scalable manufacturing processes will allow us to deliver on the next generation of nucleic acid medicines.

The following chart represents our current pipeline:

### Key Updates on our COVID-19 Vaccine Program

#### Phase 1/2 Study in United States and Singapore

In January 2022, we published (01/24/2022) immunogenicity data for participants of a Phase 1/2 booster study being conducted in the U.S. and Singapore. Results from the arms where participants were dosed with 5 mcg of ARCT-154 as a booster after at least five months of being vaccinated with two doses of Comirnaty showed encouraging increases in levels of neutralizing antibody activity against D614G and several variants of concern (VoCs) and variants of interest (VoIs). In May 2022, we provided additional neutralization antibody activity data from Day 91 showing durability of neutralizing antibody response. Validated pseudovirus microneutralization (MNT) assay results for D614G variant showed a 28- and 40-fold increase in geometric mean fold rise (GMFR) on Day 15 and 29 after booster dose compared to pre-dose levels, respectively. The antibody levels remained elevated at 30-fold for D91 over pre-boost levels indicating the durability of the neutralizing antibody response. We also shared immunogenicity data obtained in a validated MNT assay against Beta variant and the data indicated similar durability of the neutralizing antibody response with the increases in GMFR of 26-, 31-, and -24 at days 15, 29, and 91, respectively.

**Figure:** Validated pseudovirus microneutralization (MNT) assay results (left: D614G; right: Beta), showing GMFR levels of neutralizing antibody responses over Day 1 (baseline levels prior to boosting with ARCT-154) based on geometric mean concentrations (with 95% confidence intervals) obtained for participants (for D614G: n = 12/12 for Days 1, 91 and 11/12 for Days 15 29; For Beta: n = 12/12 for Days 1, 29, 91 and 11/12 for Day 15)

In the May 2022 press release, we announced that ARCT-154 booster administered arms also demonstrated robust and durable neutralizing antibody responses against VOCs strains including the Beta and the Delta, and VOIs SARS-CoV-2 strains in a surrogate virus neutralization (sVNT) assay through Day 91.

**Figure:** Surrogate virus neutralization (sVNT) assay results for SARS-CoV-2 variants. The panel shows GMFR on Days 15, 29, and 91 over Day 1 (pre-boost baseline levels; n = 12/12 for Days 1, 29, 91; n = 11/12 for Day 15). VOCs = Variants of Concern; VOIs = Variants of Interest

From the same Phase 1/2 booster trial, we also reported data (exploratory MNT assay; Moore Laboratory, National Institute for Communicable Diseases and University of the Witwatersrand, South Africa) demonstrating neutralizing antibody immune response to SARS-CoV-2 Omicron variants, BA.1 and BA.2, in participants that received ARCT-154 as booster. Omicron-specific pseudovirus MNT assay results demonstrated neutralizing antibody titers of 54-fold (BA.1) and 46-fold (BA.2) GMFRs over baseline on Day 29 post-boost in ARCT-154 arm (n=12). The sera samples from study participants will be further analyzed for neutralizing antibody activity post-boost with ARCT-154 against different strains of SARS-CoV-2 over a period of timepoints to assess magnitude and duration of response.

**Figure:** Pseudovirus MNT assay (exploratory assay; Moore Laboratory, National Institute for Communicable Diseases and University of the Witwatersrand, South Africa) showing GMFR levels of neutralizing antibody responses over Day 1 (baseline levels prior to boosting with ARCT-154) calculated using geometric mean concentrations (with 95% confidence intervals) obtained from participants measured at Days 1 and 29 (n = 12/12).

#### Phase 1/2/3 Study in Vietnam

During 2021, we entered into a significant collaboration with Vinbiocare Biotechnology Joint Stock Company (Vinbiocare), a member company of the Vingroup Joint Stock Company (Vingroup) group of companies, whereby we provide technical expertise and support services to Vinbiocare to assist in the build out of a manufacturing facility in Vietnam. Together with Vinbiocare, we advanced ARCT-154, our investigational next generation, self-amplifying mRNA-based vaccine for COVID-19, into a Phase 1/2/3 study in Vietnam, which is being funded and sponsored by Vinbiocare. The trial is randomized, observer-blinded, placebo and active-controlled and is intended to assess the safety, immunogenicity and efficacy of ARCT-154. The Phase 3 arm of the Phase 1/2/3 study was initiated in September 2021. The study enrolled over 19,000 adult subjects in Vietnam, including individuals with medical conditions putting them at higher risk of severe complications of COVID-19. The Phase 3 placebo-controlled efficacy portion of the study enrolled over 16,000 participants.

In February 2022, our partner, Vinbiocare, completed the submission to the Vietnam Ministry of Health of ARCT-154 Emergency Use Authorization (EUA) application, which includes the safety and immunogenicity data from the placebo-controlled Phase 1/2/3a portions of the study with approximately 1,000 participants. In April 2022, Vinbiocare submitted results from the vaccine safety and efficacy analysis of the Phase 3b portion study to the Vietnam Ministry of Health to complement the data package under review for potential EUA of ARCT-154. The vaccine primary efficacy endpoint in the placebo-controlled Phase 3b portion of the study was met. Analysis of the data demonstrated that two 5-mcg doses of ARCT-154 administered 28 days apart resulted in vaccine efficacy of 55.0% (95% CI; 46.9% - 61.9%) for protection against COVID-19 overall and 95.3% (95% CI; 80.4% - 98.9%) against severe and fatal COVID-19, respectively. Nine COVID-19 related deaths were reported in the placebo group and one in the ARCT-154 vaccinated group. The single death in the ARCT-154 vaccination arm occurred in an older age group participant who was also at increased risk of severe COVID-19. During the window when COVID-19 cases in the study were detected, the prevalent SARS-CoV-2 strains associated with COVID-19 infections in Vietnam were Delta and Omicron (https://covariants.org/per-country; https://covid19.who.int/region/wpro/country/vn; https://ourworldindata.org COVID-19 Data Explorer - Vietnam Link).

Review of safety data has been performed by Vinbiocare from over 17,000 participants in the placebo-controlled Phase 1/2/3 portions through one month after second dose of ARCT-154. The incidence of unsolicited events was found to be comparable in the vaccinated and placebo groups and no incidence of myocarditis or pericarditis have been reported so far. Analysis of solicited events also demonstrated that most events were mild or moderate in severity. An independent review by the Data Safety Monitoring Board has advised for the study to continue without modification.

Additional data shared by Vinbiocare shows that the study also met the immunogenicity primary endpoint, with 98.4% 4-fold seroconversion for ancestral (Wuhan) strain, measured by surrogate virus neuralization test (sVNT) 28 days after the second dose of ARCT-154. This analysis was conducted in the first approximately 1,000 participants enrolled in the Phase 1/2/3a study and was provided earlier by Vinbiocare to the Vietnam Ministry of Health as part of the filing for EUA. More comprehensive immunogenicity, efficacy and safety data from the study will be disclosed at a later time.

#### Pivotal Booster Study

Based on the encouraging Phase 3 results of ARCT-154, which became the first documented instance of a self-amplifying mRNA vaccine candidate to demonstrate meaningful protection against COVID-19 disease in a pivotal primary vaccination trial, we have initiated start-up activities with an international CRO toward a pivotal booster trial intended to support global registration as a booster vaccination.

### Key Updates on our Other Development Candidates

- LUNAR-FLU - We have added a self-amplifying mRNA approach for our LUNAR-FLU program as well. A clinical candidate based on our STARR™ platform is expected to be identified by the year end and a Clinical Trial Application is anticipated to be filed in 2023.
- LUNAR-OTC/ARCT-810 - Our rare disease program for ornithine transcarbamylase (OTC) deficiency is continuing to advance. With the improvement of the COVID-19 scenario, there was a significant uptick in recruitment and enrollment activity for the Phase 1b ascending-dose study of ARCT-810 in 12 adults with OTC deficiency. Dosing of the first cohort (0.2 mg/kg) has completed, and the Safety Review Committee has approved dose escalation for the second cohort. Screening for the second cohort has commenced, and sites have identified a sufficient number of subjects to potentially complete study enrollment in the second half of 2022. The study is expected to complete in the fourth quarter of this year. In addition, health authorities in the UK, Belgium and Spain have approved a randomized, double-blind, placebo-controlled, nested single and multiple ascending dose Phase 2 study of ARCT-810 in 24 adolescent and adult patients with OTC-deficiency. We anticipate dosing to commence in the second quarter of 2022 and to receive interim data in a subset of patients in the second half of 2022.
- LUNAR-CF/ARCT-032 – In our preclinical program for cystic fibrosis, which is being supported in part by the Cystic Fibrosis Foundation, nonclinical and preclinical studies have led to the identification of a Preclinical Candidate and nebulizer system that should allow this product to be advanced into clinical development. We expect to file an application for a first-in-human study for ARCT-032 , our mRNA therapeutic candidate for CF, in the second half of 2022.

### Key Updates on our Research and Platform Activities

- We have several partnered programs. Recently, we reported achieving an R&D milestone in the LUNAR-HBV program as part of our collaboration with Janssen Pharmaceuticals, Inc. A LUNAR-GSDIII candidate, developed by Arcturus in collaboration with Ultragenyx is being evaluated in a Phase 1/2 clinical trial in adults with Glycogen Storage Disease Type III sponsored by Ultragenyx.
- We continue to conduct exploratory platform development activities, including the evaluation of genome editing, and new targeting approaches, where our LUNAR® and STARR™ platforms could potentially be useful for identification and development of additional products for our portfolio.

### Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Report and our audited financial statements and related notes for the year ended December 31, 2021. Our historical results of operations and the year-to-year comparisons of our results of operations that follow are not necessarily indicative of future results.

### Revenue

We enter into arrangements with pharmaceutical and biotechnology partners and government agencies that may contain upfront payments, license fees for research and development arrangements, research and development funding, milestone payments, option exercise and exclusivity fees, royalties on future sales, consulting fees and payments for technology transfers. The following table summarizes our total revenues for the periods indicated (in thousands):

*(Dollars in thousands)*

|  | Three Months Ended March 31, 2022 | 2021 | 2021 to 2022 $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $5,244 | $2,127 | $3,117 | 146.5% |

Revenue increased by $3.1 million during the three months ended March 31, 2022 as compared to the three months ended March 31, 2021. The increase in revenue primarily relates to $2.9 million revenue from the new agreement with Vinbiocare. The remaining increase of $0.2 million was from our existing collaboration partners.

Our operating expenses consist of research and development and general and administrative expenses.

*(Dollars in thousands)*

| Operating expenses: | Three Months Ended March 31, 2022 | 2021 | 2021 to 2022 $ change | % change |
| --- | ---: | ---: | ---: | --- |
| Research and development, net | $44,893 | $50,050 | $(5,157) | \* |
| General and administrative | 10,730 | 9,743 | 987 | 10.1% |
| Total | $55,623 | $59,793 | $(4,170) | \* |

#### \* Greater than 100%

The following table presents our total research and development expenses by category:

*(Dollars in thousands)*

| External pipeline development expenses: | Three Months Ended March 31, 2022 | 2021 | 2021 to 2022 $ change | % change |
| --- | ---: | ---: | ---: | --- |
| LUNAR-COVID, net | $27,816 | $29,312 | $(1,496) | -5.1% |
| LUNAR-CF, net | 1,127 | 1,404 | (277) | -19.7% |
| LUNAR-OTC | 1,645 | 3,086 | (1,441) | -46.7% |
| Discovery technologies | 1,365 | 7,845 | (6,480) | \* |
| External platform development expenses: |  |  |  |  |
| Partnered discovery technologies | 779 | 463 | 316 | \* |
| Total development expenses | $32,732 | $42,110 | $(9,378) | \* |
| Personnel related expenses | $10,317 | $6,909 | $3,408 | \* |
| Facilities and equipment expenses | 1,844 | 1,031 | 813 | 78.9% |
| Total research and development expenses, net | $44,893 | $50,050 | $(5,157) | \* |

#### \* Greater than 100%

### Research and Development Expenses, net

Our research and development expenses consist primarily of external manufacturing costs, in-vivo research studies and clinical trials performed by contract research organizations, clinical and regulatory consultants, personnel related expenses and laboratory supplies related to conducting research and development activities. Costs to acquire and manufacture pre-launch inventory, mRNA supply for preclinical studies and clinical trials are recognized and included in external pipeline development expenses for the specific program.

LUNAR-COVID expenses decreased by $1.5 million during the three months ended March 31, 2022, respectively, as compared to 2021. The decrease in the current period is primarily due increased manufacturing during the three months ended March 31, 2021 which was related to the build up of pre-launch inventory. The expense for the three months ended March 31, 2021 was partially offset by funds awarded by the Singapore EDB.

LUNAR-CF expenses were relatively consistent during the three months ended March 31, 2022 when compared to the three months ended March 31, 2021, decreasing by $0.3 million. Expenses incurred were partially offset with funds awarded by the CFF. We expect that our development efforts and associated costs will increase over the next several years as the LUNAR-CF program moves toward expected CTA submission in the third quarter of 2022.

LUNAR-OTC expenses decreased by $1.4 million during the three months ended March 31, 2022, respectively, as compared to 2021. The decrease is related to slower than expected recruiting for the ARCT-810 clinical trial caused in part by the ongoing Covid environment.

Discovery technologies represents our efforts to expand our product pipeline and are expected to remain relatively consistent in the near future. Partnered discovery technologies decreased by $6.5 million during the three months ended March 31, 2022, respectively, as compared to 2021. The decrease is primarily because in the first quarter of 2021 we acquired an exclusive license from Alexion Pharmaceuticals to certain intellectual property for approximately $5.0 million of our common stock, which we expensed in the first quarter of 2021. The remaining decrease of $1.5 million was primarily due to decreased utilization of external development resources.

Within our platform development expenses, our partnered discovery expenses with our current partners are expected to fluctuate based on the needs of our collaboration partners. Platform development expenses were relatively consistent, increasing by $0.3 million during the three months ended March 31, 2022 when compared to the three months ended March 31, 2021.

Personnel related expenses, net of funds received from CFF, increased by $3.4 million during the three months ended March 31, 2022, respectively, as compared to 2021. The increases were associated with increased headcount costs necessary to advance our external pipeline, platform and clinical trial efforts as well as increased share-based compensation expense.

Facilities and equipment expenses increased by $0.8 million during the three months ended March 31, 2022, respectively, as compared to 2021. The increase is primarily due to higher rent and costs associated with preparing our additional facility to be ready for occupancy in the second quarter of 2022.

### General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related benefits for our executive, administrative and accounting functions and professional service fees for legal and accounting services as well as other general and administrative expenses.

General and administrative expenses increased by $1.0 million during the three months ended March 31, 2022, as compared to 2021. The increases resulted primarily from personnel expense due to increased headcount and increased share-based compensation expense.

### Finance (expense) income, net

*(Dollars in thousands)*

|  | Three Months Ended March 31, 2022 | 2021 | 2021 to 2022 $ change | % change |
| --- | ---: | ---: | ---: | --- |
| Interest income | $154 | $188 | $(34) | -18.1% |
| Interest expense | (718) | (546) | (172) | \* |
| Total | $(564) | $(358) | $(206) | \* |

#### \* Greater than 100%

Interest income is generated on cash and cash equivalents. The decrease in interest income for the three months ended March 31, 2022 as compared to the prior year period was a result of decreased cash and cash equivalents balances. Interest expense was incurred in conjunction with our Loan and Security Agreement with Western Alliance Bank and the Singapore Loan. The increase in interest expense for the three months ended March 31, 2022 as compared to the prior year period was primarily a result of additional accrued interest expense related to the Singapore Loan that was funded in January 2021.

### Other income and expense

Other income and expense items relate to gains and losses from foreign currency transactions and from equity-method investments. During the three months ended March 31, 2022 and March 31, 2021, we recorded a loss of $0.4 million and a gain of $1.2 million, respectively, in connection with our equity-method investment in Vallon Pharmaceuticals, Inc., of which we hold approximately 12%.

### Off-balance sheet arrangements

Through March 31, 2022, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

### Liquidity and Capital Resources

From the Company’s inception through the quarter ended March 31, 2022, the Company has funded its operations principally with the proceeds from the sale of capital stock, long-term debt and revenues earned through collaboration agreements. At March 31, 2022, we had $319.7 million in unrestricted cash and cash equivalents.

#### Loan and Security Agreement

On October 12, 2018, we entered into a Loan and Security Agreement with Western Alliance Bank whereby we received gross proceeds of $10.0 million under a long-term debt agreement (the “Loan Agreement”).

On October 30, 2019, we and the Bank entered into a Third Amendment (the “Third Amendment”) to the Loan Agreement and on December 31, 2020 Arcturus Therapeutics, Inc. and the Bank entered into a Fourth Amendment (the “Fourth Amendment”) to the Loan Agreement (as amended, the “Loan Agreement”). The Fourth Amendment was executed in connection with the Singapore Loan.

Pursuant to the Third Amendment, the Bank agreed to make a term loan to us on October 30, 2019, in the amount of $15.0 million (the “Term Loan”). The resulting net increase in the indebtedness of us was $5.0 million. The Term Loan bears interest at a floating rate ranging from 1.25% to 2.75% above the prime rate. The amendment further provides that the Term Loan has a maturity date of October 30, 2023. We shall make monthly payments of interest only until the interest-only end date of August 1, 2022.

#### Manufacturing Support Agreement

On November 7, 2020, we entered into a Manufacturing Support Agreement (the “Support Agreement”) with the EDB. Pursuant to the Support Agreement, the EDB agreed to make a term loan of S$62.1 million, subject to the satisfaction of customary deliveries, to support the manufacture of the LUNAR-COV19 vaccine candidate (the “Singapore Loan”). The EDB has agreed to an extension of the reconciliation period to March 31, 2022 with unused funds as of such date to be subsequently returned within thirty days, subject to any further agreed upon extension of the reconciliation date. The parties are in continued negotiations with respect to amendments of the Singapore Loan terms. Under current terms, (i) we are to provide a quarterly reconciliation report within forty-five days of each financial quarter end, (ii) we provided a schedule of expenditures through March 31, 2022 which will be followed by an audited statement of actual expenditures through March 31, 2022 by June 30, 2022, (iii) we are to provide EDB with a right of first refusal on GMP manufacturing slots of the LUNAR-COV19 vaccine candidate up to an agreed-upon maximum amount, (iv) and the obligation to repay the Singapore Loan will be secured by an interest in the raw materials and manufacturing equipment purchased by us with the funds from the Singapore Loan in form and substance satisfactory to the EDB in its sole discretion. We elected to borrow the full amount available under the Support Agreement of S$62.1 million ($46.6 million) on January 29, 2021. As of March 31, 2022, the Company has reported a portion of the Singapore Loan as current to reflect a potential principal repayment of approximately 20.9 million Singapore dollars (US $15.4 million) in fiscal year 2022 based on amounts not used toward the manufacture of ARCT-021 and is expecting to refund this portion during the third quarter of 2022.

The Singapore Loan accrues interest at a rate of 4.5% per annum calculated on a daily basis. At the end of each fiscal year, accrued interest is added to the principal amount of the loan and bears additional interest accordingly. Subject to certain exceptions, the Singapore Loan is intended to be a limited recourse loan that will be repaid solely through a royalty payment of 10% of net sales proceeds of the LUNAR-COV19 vaccine candidate, up to the amount of the outstanding principal and interest under the Singapore Loan. However, all unpaid principal and interest under the Singapore Loan will be due and payable five years after draw date, if net sales of the LUNAR-COV19 vaccine exceed a certain minimum threshold during this five year period or we obtain clearance to sell the vaccine in specified jurisdictions. Unpaid principal and interest under the Singapore Loan will also become due and payable upon an event of default under the Support Agreement. The first vaccine sales, including the amount of net sales, shall be reported to EDB within 10 days of delivery and quarterly reports of aggregate vaccine sales, including net sales proceeds shall be provided within 30 days after quarter end.

The Singapore Loan is forgivable if we have not obtained regulatory approval by the final repayment date and net sales of LUNAR-COV19 are less than $100 million. If, any portion of the Singapore Loan is required to be forgiven pursuant to the terms of the Support Agreement, the EDB has the right to take ownership of certain raw materials and equipment that were purchased by us with proceeds of the Singapore Loan (the “Specified Assets”). We entered into a security agreement (the “Security Agreement”) for the benefit of the EDB to provide that repayment of the Singapore Loan and related obligations are secured by a lien on the Specified Assets.

In connection with the entry into the Support Agreement, we entered into a consent agreement with Western Alliance Bank (the “Bank”) and an amendment to the Loan and Security Agreement, dated as of October 12, 2018, to exclude the Specified Assets from Western Alliance Bank’s lien on certain assets.

#### Vinbiocare Agreement

On August 2, 2021, we announced an agreement with Vinbiocare, a member of Vingroup Joint Stock Company, to establish a manufacturing facility in Vietnam for the manufacture of our investigational COVID-19 vaccine program, for sale and use within Vietnam. In addition, Vinbiocare agreed to execute a phase 1/2/3 study in Vietnam.

Under the terms of the arrangement, Vinbiocare is building out a manufacturing facility in Vietnam, and we have provided to Vinbiocare access to proprietary technologies and processes for the manufacture of our investigational COVID-19 vaccine candidate. We also provided Vinbiocare with an exclusive license to manufacture the vaccines in Vietnam at the facility solely for distribution in Vietnam. The license and technology transfer applies toward drug product manufacturing but not toward mRNA drug substance manufacturing. Vinbiocare made an upfront payment of $40 million and is responsible for costs associated with the technology transfer. Vinbiocare will also pay for mRNA drug substance supplied by us and royalties on vaccines produced at the manufacturing facility.

#### General Financial Resources

A significant portion of our current unrestricted cash and cash equivalents balance of $319.7 million is expected to be utilized during fiscal year 2022 to fund (i) a portion of the planned COVID Booster trial, (ii) further progress of our FLU vaccine programs, (iii) the continued Phase 2 trial of ARCT-810, our LUNAR-OTC candidate, (iv) advances to our LUNAR-CF program toward submission of a CTA during the second half of 2022 and (v) continued expansion of our platform and other general administrative activities.

Our future capital requirements are difficult to forecast and will depend on many factors that are out of our control. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that we will be able to obtain additional needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of our existing shareholders.

We expect to continue to incur additional losses for the foreseeable future, and we will need to raise additional debt or equity financing or enter into additional partnerships to fund development. The ability of our Company to transition to profitability is dependent on identifying and developing successful mRNA drug candidates. If we are not able to achieve planned milestones, incur costs in excess of our forecasts, or do not meet covenant requirements of our debt, we will need to reduce discretionary spending, discontinue the development of some or all of our products, which will delay part of our development programs, all of which will have a material adverse effect on our ability to achieve our intended business objectives.

### Overview

The following table shows a summary of our cash flows for the three months ended March 31, 2022 and 2021 (in thousands):

*(Dollars in thousands)*

| Cash provided by (used in): | Three Months Ended March 31, 2022 | 2021 |
| --- | ---: | ---: |
| Operating activities | $(49,039) | $(42,950) |
| Investing activities | (2,111) | (118) |
| Financing activities | 336 | 47,012 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | $(50,814) | $3,944 |

### Operating Activities

Our primary use of cash is to fund operating expenses, which consist mainly of research and development, clinical studies, manufacturing drug substance and drug product and general and administrative expenditures. We have incurred significant expenses which have been partially offset by cash collected through our collaboration agreements. Cash collections under the collaboration agreements can vary from year to year depending on the terms of the agreement and work performed. These changes in cash flows primarily relate to the timing of cash receipts for upfront payments, reimbursable expenses and achievement of milestones under these collaborative agreements.

Net cash used in operating activities was $49.0 million on a net loss of $54.1 million for the three months ended March 31, 2022, compared to net cash used of $42.9 million on a net loss of $56.3 million for the three months ended March 31, 2021. Adjustments for non-cash charges which includes share-based compensation expense and depreciation and amortization were $8.7 million and $11.3 million for the three months ended March 31, 2022 and 2021, respectively. Changes in working capital resulted in adjustments to operating net cash outflows of $3.7 million and inflows of $2.1 million for the three months ended March 31, 2022 and 2021, respectively. Changes in working capital for the three months ended March 31, 2022 were primarily driven by decreases in deferred revenue and accrued liabilities, partly offset by increases in accounts payable and prepaid expenses. Changes in working capital for the three months ended March 31, 2021 were primarily driven by an increase in accounts payable and accrued liabilities and a decrease in prepaid expenses, partly offset by a decrease in deferred revenue.

### Investing Activities

Net cash used in investing activities of $2.1 million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively, reflects cash used to purchase property and equipment.

### Financing Activities

Net cash provided by financing activities of $0.3 million for the three months ended March 31, 2022 consisted of net proceeds from the exercise of stock options. Net cash provided by financing activities of $47.0 million for the three months ended March 31, 2021 consisted of net proceeds from debt related to the Singapore Loan of $46.6 million and proceeds from the exercises of stock options of $0.4 million.

### Funding Requirements

We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin commercialization of our products. As a result, we will require additional capital to fund our operations in order to support our long-term plans. We believe that our current cash position will be sufficient to meet our anticipated cash requirements through at least the next twelve months, assuming, among other things, no significant unforeseen expenses, continued funding from partners at anticipated levels and our payment obligations continuing to follow the current maturity schedule under our long-term credit facility referenced in Note 5. We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, liquidate our assets, file for bankruptcy, reorganize, merge with another entity, or cease operations.

Our future funding requirements are difficult to forecast and will depend on many factors, including the following:

- the development of our LUNAR-COV19 and LUNAR-FLU vaccine candidates;
- the achievement of milestones under our strategic alliance agreements;
- maintaining and/or expanding our manufacturing network and capabilities;
- the terms and timing of any other strategic alliance, licensing and other arrangements that we may establish;
- the initiation, progress, timing and completion of preclinical studies and clinical trials for our product candidates;
- the number and characteristics of product candidates that we pursue;
- the outcome, timing and cost of regulatory approvals;
- delays that may be caused by changing regulatory requirements;
- the cost and timing of hiring new employees to support our continued growth;
- the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;
- the costs and timing of procuring clinical and commercial supplies of our product candidates;
- the costs and timing of establishing sales, marketing and distribution capabilities;
- the costs associated with legal proceedings;
- the extent to which we acquire or invest in businesses, products or technologies;
- market disruptions, including significant volatility in the financial markets caused by the Russia/Ukraine conflict.

### Critical Accounting Policies and Estimates

We prepare our condensed consolidated financial statements in conformity with GAAP. As such, we make certain estimates, judgments and assumptions that we believe are reasonable, based upon information available to us. These judgements involve making estimates about the effect of matters that are inherently uncertain and may significantly impact our reported results of operations and financial condition. We describe our significant accounting policies more fully in Note 2 to our consolidated financial statements for the year ended December 31, 2021.

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in the 2021 Annual Report.

## Market risk

As filed, 926 characters.

Our primary exposure to market risk is interest income and expense sensitivity and foreign currency exchange rates. Interest income and expense sensitivity is affected by changes in the general level of interest rates in the United States. Foreign exchange market risks relate to the grants and loan from the Singapore Economic Development Board which is discussed in this Quarterly Report in “Notes to Condensed Consolidated Financial Statements, Note 1. Description of Business.” When deemed appropriate, we may manage our exposure to foreign exchange market risks through the use of derivative financial instruments. We may utilize such derivative financial instruments for hedging or risk management purposes. Due to the nature of our cash and cash equivalents and our evaluation of the potential impact of foreign currency exchange rates, we believe that we are not currently subject to any material market risk exposure.

## Controls and procedures

As filed, 1,962 characters.

### Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) and Rule 15d-15(b) of the Exchange Act, our management, including our principal executive officer, our principal financial officer and our principal accounting officer, conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, management has concluded that as of March 31, 2022, the Company’s disclosure controls and procedures were effective at the reasonable assurance level, and we believe the condensed consolidated financial statements included in this Form 10-Q for the quarterly period ended March 31, 2022 fairly present, in all material respects, our financial position, results of operations, comprehensive loss, statements of stockholders’ equity and cash flows for the periods presented in conformity with U.S. generally accepted accounting principles.

### Changes in Internal Control over Financial Reporting

As required by Rule 13a-15(d) and Rule 15d-15(d) of the Exchange Act, our management, including our principal executive officer, our principal financial officer and our principal accounting officer, conducted an evaluation of the internal control over financial reporting to determine whether any other changes occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, our principal executive officer, principal financial officer and principal accounting officer concluded that there were no changes in our internal controls over financial reporting during the period covered by this Quarterly Report on Form 10-Q that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 3,586 characters.

Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which we strongly encourage you to review. Other than as set forth below, there have been no material changes to the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Commission on March 1, 2022.

***Instability in geographies where the Company has operations and personnel or where the Company derives revenue could have a material adverse effect on the Company’s business, customers, operations and financial results.***

Economic, civil, military and political uncertainty may arise or increase in regions where we, our collaborators, critical service providers or other key third parties operate or derive revenue. Further, countries from which we, our collaborators, critical service providers or other key third parties operate or derive revenue may experience military action and/or civil and political unrest. In late February 2022, Russian military forces launched significant military action against Ukraine. Sustained conflict and disruption in the region is likely. The aggregate impact to Eastern Europe and Europe as a whole, as well as actions taken by countries or global organizations, including but not limited to new and stricter sanctions and policies by the United States, Canada, the United Kingdom, the European Union and/or the United Nations, against Russia, Belarus and Ukraine, and officials or other individuals, regions, and industries therein, is not knowable at this time. Further, potential responses to such sanctions and policies by Russia, Belarus, Ukraine, or other actors, including but not limited to increased tensions and more dramatic military actions, is not knowable at this time. Beyond the impact this conflict has had on Eastern Europe and the surrounding regions, these events have roiled global financial markets and supply chains. Any of the foregoing, individually or collectively, may have a material adverse impact on our business, financial condition and results of operations.

***Any booster study for ARCT-154 may have difficulty in its enrollment, initiation and completion. Further, the transition of the COVID-19 pandemic to an endemic stage may impact the commercial potential of ARCT-154 and our COVID-19 program.***

We have initiated start-up activities with an international CRO toward a pivotal Phase 3 booster trial for ARCT-154, our lead next-generation self-amplifying mRNA vaccine candidate. The trial would be a necessary step toward an approval of ARCT-154 as a booster and possibly for any approval in any significant market. The trial could face many challenges, including enrollment, procurement of a comparator vaccine and regulatory approvals to proceed, and we expect that additional studies would also be required for approvals. If we are unable to proceed with or complete the trial for any reason, we might not be able to achieve an approval for ARCT-154, and our COVID-19 vaccine program would be materially adversely impacted. Further, as the COVID-19 pandemic transitions to an endemic stage, the commercial potential of ARCT-154 and our COVID-19 vaccine program may be significantly reduced. As we continue to evaluate the changing environment, we may reevaluate our activities and planned expenditures on our COVID-19 vaccine program. The development of ARCT-154 also remains subject to the other risks mentioned in our Annual Report on Form 10-K for the year ended December 31, 2021.

Filed May 9, 2022.
Source: SEC EDGAR, the filing index for accession 0000950170-22-008524. Last ingested by Listed: Nov 14, 2026, 14:45 ET. No prices; not investment advice.
